Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (23786)	5/24/2007 12:11:58 PM
From: kenhott	Respond to of 52153

<But as for Nissen, the article pointed out that Takeda's drug was in the same class and that Nissen was running clinic trials on it(Actos). IMO this could be a conflict and take something away from his objectivity.> These guys compete with each other just like everyone else. So I am sure he rather liked the whole idea of shooting down Avandia given his affiliation. Like getting the whip cream on top. I have listened to him talk candidly about himself. Not my kind of guy. ahhhhh... you know what I mean.